Lori Styles is an Oncology physician affiliated with Vyne Therapeutics. OpenAlex indexes 134 publications with 8,729 citations (h-index 49); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
747 52nd Street
Oakland, CA 94609
Telephone
510-428-3372Registry record last updated 8 Jul 2007.
Clinical trials
- Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
Sponsor: Summit Therapeutics
- Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
Sponsor: Summit Therapeutics
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
NIH funding
6 NIH research awards on record, funded 1997–2009 per NIH RePORTER. The latest:
- Arginine as Prophylactic Therapy in Sickle Cell Disease
Children'S Hospital & Res Ctr at Oakland
FY2009$154,621K24HL074256 - Arginine as Prophylactic Therapy in Sickle Cell Disease
Children'S Hospital & Res Ctr at Oakland
FY2008$150,118K24HL074256 - Phospholipase A2 Inhibitor Safety Trial
Children'S Hospital & Res Ctr at Oakland
FY2007$344,536U54HL070583
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study
Journal of Clinical Oncology
2023 - Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study
Biology of Blood and Marrow Transplantation
2019
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”